Provided by Tiger Trade Technology Pte. Ltd.

ArriVent BioPharma

21.86
+0.51002.39%
Post-market: 22.400.5400+2.47%17:43 EST
Volume:488.80K
Turnover:10.72M
Market Cap:902.41M
PE:-5.23
High:22.36
Open:21.86
Low:21.42
Close:21.35
52wk High:28.12
52wk Low:15.47
Shares:41.28M
Float Shares:18.29M
Volume Ratio:0.60
T/O Rate:2.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1758
EPS(LYR):-2.5577
ROE:-51.84%
ROA:-32.78%
PB:2.96
PE(LYR):-8.55

Loading ...

Big Money Moves Out of ArriVent BioPharma

TIPRANKS
·
Feb 04

Hillhouse Investment Management Reports Disposal of ArriVent Biopharma Common Shares

Reuters
·
Feb 04

ArriVent BioPharma Up Nearly 11%, on Pace for Largest Percent Increase Since August 2024 -- Data Talk

Dow Jones
·
Jan 23

ArriVent Buy Rating: Favorable Risk‑Reward on Firmonertinib Ahead of Pivotal FURVENT Phase 3 Readout

TIPRANKS
·
Jan 12

ArriVent BioPharma Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Dec 23, 2025

BRIEF-Arrivent Announces First Patient Dosed In Global Pivotal Phase 3 Alpacca Trial Evaluating Firmonertinib For First-Line Treatment Of EGFR PACC Mutant Non-Small Cell Lung Cancer

Reuters
·
Dec 22, 2025

Arrivent Announces First Patient Dosed in Global Pivotal Phase 3 Alpacca Trial Evaluating Firmonertinib for First-Line Treatment of Egfr Pacc Mutant Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Dec 22, 2025

ArriVent BioPharma Initiated at Buy by BTIG

Dow Jones
·
Dec 10, 2025

BTIG Initiates ArriVent BioPharma at Buy With $45 Price Target

MT Newswires Live
·
Dec 10, 2025

Arrivent Biopharma Inc : Btig Initiates Coverage With Buy Rating; Price Target $45

THOMSON REUTERS
·
Dec 10, 2025

U.S. RESEARCH ROUNDUP-JP Morgan, Pepsico, Pfizer

Reuters
·
Dec 10, 2025

ArriVent BioPharma Initiated at Buy by Truist Securities

Dow Jones
·
Nov 26, 2025

Arrivent Biopharma Inc : Truist Securities Initiates Coverage With Buy Rating; Target Price $43

THOMSON REUTERS
·
Nov 25, 2025

Truist Initiates ArriVent BioPharma at Buy With $43 Price Target

MT Newswires Live
·
Nov 25, 2025

Stock Track | ArriVent BioPharma Soars 5.21% Ahead of Anticipated Q4 Earnings Report

Stock Track
·
Nov 13, 2025

Stock Track | ArriVent BioPharma Soars 5.21% Ahead of Q4 Earnings Report

Stock Track
·
Nov 13, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 12, 2025

ArriVent BioPharma, Inc.: Strategic Advancements and Promising Developments Drive Buy Rating with $45 Price Target

TIPRANKS
·
Nov 12, 2025

ArriVent BioPharma Is Maintained at Buy by Citigroup

Dow Jones
·
Nov 12, 2025

Stock Track | ArriVent BioPharma Soars 5.05% on Pipeline Updates and Bullish Analyst Rating

Stock Track
·
Nov 12, 2025